Clinical Benefits of RYBREVANT®
In a clinical trial, RYBREVANT® was studied in 81 people who had mNSCLC with EGFR exon 20 insertion mutations whose disease had worsened while on or after chemotherapy that contains platinum
- Most people in the trial were women (59%)
- Over half never smoked (53%)
- The main goal of the trial was to measure the number of people who responded to RYBREVANT® overall
40% of people treated with RYBREVANT® after chemotherapy that contains platinum saw their tumors disappear* (3.7%) or get smaller (36%).
*The disappearance of all signs of cancer in response to treatment does not always mean the cancer has been cured.
The median response time for people treated with RYBREVANT® was 11.1 months.
- This means half of people responded to RYBREVANT® for 11.1 months or longer, and half responded for less than 11.1 months
- 63% of people responded to RYBREVANT® for 6 months or longer
It's important to know what to expect while on treatment with RYBREVANT®
EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer; TKI, tyrosine kinase inhibitor.
Side Effects With RYBREVANT®
You may experience some side effects while on treatment with RYBREVANT®
There can be common and serious side effects that happen while on treatment. Keep your care team informed about how you’re feeling. They can help you manage side effects when starting—or during—treatment.
Possible serious side effects of RYBREVANT® include
Infusion-related reactions. Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®: shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, or vomiting.
Lung problems. RYBREVANT® may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
Skin problems. RYBREVANT® may cause rash, itching, and dry skin. You may use alcohol-free moisturizing cream for dry skin. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT®. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT®. Wear protective clothing and use sunscreen during treatment with RYBREVANT®.
Eye problems. RYBREVANT® may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include: eye pain, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, or sensitivity to light. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems during treatment with RYBREVANT®. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.
The most common side effects of RYBREVANT® include
- infusion-related reactions
- infected skin around the nail
- muscle and joint pain
- shortness of breath
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- sores in the mouth
- changes in certain blood tests
11% of people stopped treatment with RYBREVANT® because of side effects. 78% of people had their treatment interrupted due to side effects, and 59% of people had their infusion interrupted because of an infusion-related reaction (IRR).
What you should know about infusion-related reactions (IRRs)
Your care team is trained to help you with any IRRs you may experience, so make sure to tell them how you’re feeling during your infusion. Here are some things you should know about IRRs:
IRRs are common with RYBREVANT® and can be severe or serious
IRRs can involve shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, or vomiting that occur during your infusion
IRRs were one of the most common side effects in a clinical study, and occurred in 66% of people treated with RYBREVANT®
65% of IRRs occur on Day 1 of the first dose, and typically happen within the first hour of an infusion. On Day 2 of the first dose, 3.4% of people experienced an IRR. During Week 2, only 0.4% of people experienced an IRR. During all other infusions, 1.1% of people experienced an IRR
Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of these reactions
Pay close attention to how you feel during an infusion, and make sure to let your care team know if you experience any discomfort—they know how to help.
How RYBREVANT® Works
RYBREVANT® is the only treatment of its kind designed to target mNSCLC with EGFR exon 20 insertion mutations after chemotherapy that contains platinum
RYBREVANT® is a targeted antibody that:
- Directly blocks EGFR on the outside of the cell to stop tumors from growing
- Works with your body's immune system to identify and destroy cancer cells with EGFR